Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion

H. Lorberboum-Galski; R. Lafyatis; J. P. Case; D. FitzGerald; R. L. Wilder; I. Pastan

doi:10.1016/0192-0561(91)90112-K

Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion

H. Lorberboum-Galski^*, R. Lafyatis, J. P. Case, D. FitzGerald, R. L. Wilder, I. Pastan

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

IL-2-PE40 is a chimeric cytotoxin composed of interleukin 2 (IL-2) fused to a truncated form of Pseudomonas exotoxin (PE) that lacks its binding domain. IL-2-PE40 has been shown to exhibit therapeutic potency in several models in vivo when adminstered i.p. twice a day. Here we show that the continuous administration of IL-2-PE40 by an osmotic pump specifically prevents the development of adjuvant induced arthritis in rats with an improved therapeutic efficacy as compared to daily repeated i.p. injections. Stabilization of IL-2-PE40 at 37°C for the continuous administration by pumps was achieved by adding NAD, the substrate for the enzyme portion of the chimeric toxin.

Original language	English
Pages (from-to)	305-315
Number of pages	11
Journal	International Journal of Immunopharmacology
Volume	13
Issue number	2-3
DOIs	https://doi.org/10.1016/0192-0561(91)90112-K
State	Published - 1991
Externally published	Yes

Bibliographical note

Funding Information:
*Laboratory of Molecular Biology, Division of Cancer Biology and Diagnosis, National Cancer Institute and +Arthritis and Rheumatism, Connective Tissue Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, U.S.A.

Access to Document

10.1016/0192-0561(91)90112-K

Cite this

Lorberboum-Galski, H., Lafyatis, R., Case, J. P., FitzGerald, D., Wilder, R. L., & Pastan, I. (1991). Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. International Journal of Immunopharmacology, 13(2-3), 305-315. https://doi.org/10.1016/0192-0561(91)90112-K

@article{55753ef18a5a47a6b1ec95c60cee93e7,

title = "Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion",

abstract = "IL-2-PE40 is a chimeric cytotoxin composed of interleukin 2 (IL-2) fused to a truncated form of Pseudomonas exotoxin (PE) that lacks its binding domain. IL-2-PE40 has been shown to exhibit therapeutic potency in several models in vivo when adminstered i.p. twice a day. Here we show that the continuous administration of IL-2-PE40 by an osmotic pump specifically prevents the development of adjuvant induced arthritis in rats with an improved therapeutic efficacy as compared to daily repeated i.p. injections. Stabilization of IL-2-PE40 at 37°C for the continuous administration by pumps was achieved by adding NAD, the substrate for the enzyme portion of the chimeric toxin.",

author = "H. Lorberboum-Galski and R. Lafyatis and Case, {J. P.} and D. FitzGerald and Wilder, {R. L.} and I. Pastan",

note = "Funding Information: *Laboratory of Molecular Biology, Division of Cancer Biology and Diagnosis, National Cancer Institute and +Arthritis and Rheumatism, Connective Tissue Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, U.S.A.",

year = "1991",

doi = "10.1016/0192-0561(91)90112-K",

language = "אנגלית",

volume = "13",

pages = "305--315",

journal = "International Journal of Immunopharmacology",

issn = "0192-0561",

publisher = "Elsevier",

number = "2-3",

}

Lorberboum-Galski, H, Lafyatis, R, Case, JP, FitzGerald, D, Wilder, RL & Pastan, I 1991, 'Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion', International Journal of Immunopharmacology, vol. 13, no. 2-3, pp. 305-315. https://doi.org/10.1016/0192-0561(91)90112-K

Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. / Lorberboum-Galski, H.; Lafyatis, R.; Case, J. P. et al.
In: International Journal of Immunopharmacology, Vol. 13, No. 2-3, 1991, p. 305-315.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion

AU - Lorberboum-Galski, H.

AU - Lafyatis, R.

AU - Case, J. P.

AU - FitzGerald, D.

AU - Wilder, R. L.

AU - Pastan, I.

N1 - Funding Information: *Laboratory of Molecular Biology, Division of Cancer Biology and Diagnosis, National Cancer Institute and +Arthritis and Rheumatism, Connective Tissue Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, U.S.A.

PY - 1991

Y1 - 1991

N2 - IL-2-PE40 is a chimeric cytotoxin composed of interleukin 2 (IL-2) fused to a truncated form of Pseudomonas exotoxin (PE) that lacks its binding domain. IL-2-PE40 has been shown to exhibit therapeutic potency in several models in vivo when adminstered i.p. twice a day. Here we show that the continuous administration of IL-2-PE40 by an osmotic pump specifically prevents the development of adjuvant induced arthritis in rats with an improved therapeutic efficacy as compared to daily repeated i.p. injections. Stabilization of IL-2-PE40 at 37°C for the continuous administration by pumps was achieved by adding NAD, the substrate for the enzyme portion of the chimeric toxin.

AB - IL-2-PE40 is a chimeric cytotoxin composed of interleukin 2 (IL-2) fused to a truncated form of Pseudomonas exotoxin (PE) that lacks its binding domain. IL-2-PE40 has been shown to exhibit therapeutic potency in several models in vivo when adminstered i.p. twice a day. Here we show that the continuous administration of IL-2-PE40 by an osmotic pump specifically prevents the development of adjuvant induced arthritis in rats with an improved therapeutic efficacy as compared to daily repeated i.p. injections. Stabilization of IL-2-PE40 at 37°C for the continuous administration by pumps was achieved by adding NAD, the substrate for the enzyme portion of the chimeric toxin.

UR - http://www.scopus.com/inward/record.url?scp=0025969219&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(91)90112-K

DO - 10.1016/0192-0561(91)90112-K

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 2071302

AN - SCOPUS:0025969219

SN - 0192-0561

VL - 13

SP - 305

EP - 315

JO - International Journal of Immunopharmacology

JF - International Journal of Immunopharmacology

IS - 2-3

ER -

Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this